Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | EIF4A3 | P38919 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 4/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5947744 | 0.86 | EIF4A3 (0.53) | KIF11EIF4A3SCN10AKDM4EGAA | |
| SCHEMBL24781197 | 0.84 | KDM4E (0.41) | KIF11EIF4A3PTGS2HDAC6SCN10A | |
| SCHEMBL9910163 | 0.79 | CYP2A6 (0.55) | KIF11EIF4A3PTGS2HDAC6SCN10A | |
| SCHEMBL1102337 | 0.76 | LOXL2 (0.50) | CYP2A6KEAP1KDM4EGAAMAPT | |
| SCHEMBL3434958 | 0.76 | KIF11 (0.46) | KIF11SYKSCN10ACFTRCYP2A6 | |
| SCHEMBL889309 | 0.76 | KIF11 (0.42) | KIF11EIF4A3PTGS2HDAC6SCN10A | |
| SCHEMBL31276626 | 0.76 | KIF11 (0.46) | KIF11SYKSCN10ACFTRCYP2A6 | |
| SCHEMBL13923569 | 0.76 | LOXL2 (0.50) | KDM4EGAALMNAMAPT | |
| SCHEMBL19352880 | 0.74 | SYK (0.37) | KIF11SYKCFTRCYP2A6KEAP1 | |
| SCHEMBL12025195 | 0.74 | FLT3 (0.50) | SYKGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11856955-B2 | Binary compositions as disruptors of Orco-mediated odorant sensing | VANDERBILT UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230295200-A1 | STAT5 and STAT6 Inhibitors and Uses Thereof | UNIV MICHIGAN (US) | 2023-09-21 | — | — | US | disclosed |
| US-11713305-B2 | Zinc sensors for in vivo imaging of beta-cell function by MRI | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220015893-A1 | METHOD OF ADJUSTING A BLENDED EXTENDED DEPTH OF FOCUS LIGHT ADJUSTABLE LENS WITH LATERALLY OFFSET AXES | RXSIGHT, INC. | 2022-01-20 | — | — | US | disclosed |
| US-11192852-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | REATA PHARMACEUTICALS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-11092549-B2 | Fluorescent probes for drug permeability in gram negative bacteria | SAINT LOUIS UNIVERSITY (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210147380-A1 | CYSTEINE-DEPENDENT INVERSE AGONISTS OF NUCLEAR RECEPTORS ROR-GAMMA/ROR-GAMMA-T AND METHODS OF TREATING DISEASES OR DISORDERS THEREWITH | REATA PHARMACEUTICALS, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-20200390099-A1 | BINARY COMPOSITIONS AS DISRUPTORS OF ORCO-MEDIATED ODORANT SENSING | UNIV VANDERBILT (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200207706-A1 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200157078-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-9670147-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | REATA PHARMACEUTICALS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9127021-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-8933110-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8653070-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20090069282-A1 | ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207706-A1 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | GPX4, MPO, GPX1 | KIF11 4877/4885EIF4A3 961/4885PTGS2 31/4885 |
| US-11856955-B2 | Binary compositions as disruptors of Orco-mediated odorant sensing | OR51E2, OR10J3, ORC3 | KIF11 3102/4885EIF4A3 1596/4885PTGS2 4706/4885 |
| US-11192852-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | GPX4, MPO, GPX1 | KIF11 4877/4885EIF4A3 961/4885PTGS2 31/4885 |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KIF11 3339/4885EIF4A3 62/4885PTGS2 1567/4885 |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KIF11 3339/4885EIF4A3 62/4885PTGS2 1567/4885 |
| US-20210147380-A1 | CYSTEINE-DEPENDENT INVERSE AGONISTS OF NUCLEAR RECEPTORS ROR-GAMMA/ROR-GAMMA-T AND METHODS OF TREATING DISEASES OR DISORDERS THEREWITH | RORC, RORA, RORB | KIF11 4149/4885EIF4A3 4121/4885PTGS2 846/4885 |
| US-20200157078-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESRRG, ESR1 | KIF11 4689/4885EIF4A3 4103/4885PTGS2 1352/4885 |
| US-20090069282-A1 | ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | KIF11 3445/4885EIF4A3 2061/4885PTGS2 3528/4885 |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KIF11 3339/4885EIF4A3 62/4885PTGS2 1567/4885 |
| US-11713305-B2 | Zinc sensors for in vivo imaging of beta-cell function by MRI | IAPP, SLC30A6, NCS1 | KIF11 3736/4885EIF4A3 4456/4885PTGS2 3050/4885 |
| US-11092549-B2 | Fluorescent probes for drug permeability in gram negative bacteria | SLC47A2, SLC47A1, ABCB11 | KIF11 3124/4885EIF4A3 4758/4885PTGS2 1164/4885 |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | NSUN2, HCCS, HAVCR2 | KIF11 2987/4885EIF4A3 127/4885PTGS2 1803/4885 |
| US-20230295200-A1 | STAT5 and STAT6 Inhibitors and Uses Thereof | STAT6, STAT5B, STAT5A | KIF11 3607/4885EIF4A3 1234/4885PTGS2 3398/4885 |
| US-20200390099-A1 | BINARY COMPOSITIONS AS DISRUPTORS OF ORCO-MEDIATED ODORANT SENSING | OR51E2, OR10J3, ORC3 | KIF11 3102/4885EIF4A3 1596/4885PTGS2 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.